Pemvidutide

1. Pemvidutide has no effect on QTcF in humans (<10 ms).

   “mean (90% CI) predicted placebo-corrected change in QTcF (∆∆QTcF) was <10 ms at all pemvidutide concentrations”

   Human trial12 weeks

   Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

More on QTcF

1. Pemvidutide has no effect on heart rate in humans.

   “without dose-related or clinically meaningful effects on RPP or HR or imbalances in cardiac adverse events”

   Human trial

   Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

More on Heart rate

1. Pemvidutide decreases diastolic blood pressure in humans (up to 6.5 mmHg).

   “reductions in SBP and DBP up to 13.0 mmHg and 6.5 mmHg, respectively, were observed”

   Human trial

   Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

More on Diastolic blood pressure

1. Pemvidutide decreases systolic blood pressure in humans (up to 13.0 mmHg).

   “reductions in SBP and DBP up to 13.0 mmHg and 6.5 mmHg, respectively, were observed”

   Human trial

   Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

More on Systolic blood pressure

1. Pemvidutide decreases visceral adipose tissue mass in humans (-28.3%).

   “VAT mass decreased by up to 28.3% at the 2.4 mg dose at Week 48.”

   Human trialoverweight or obesityvisceral adipose tissue2.4 mg48 weeksn = 67

   Noninvasive Tests of Central Adiposity Correlate with Reductions in MRI-Measured Visceral Adipose Tissue Mass in Subjects with Overweight or Obesity Treated with Pemvidutide

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

More on Visceral adipose tissue mass

1. Pemvidutide decreases Glyc-A in humans.

   “Reductions in Glyc-A, a biomarker correlated with heart failure, were also observed”

   Human trialsubcutaneous48 weeksn = 254

   Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

More on Glyc-A

1. Pemvidutide decreases triglyceride in humans (up to 34.9%).

   “Pemvidutide reduced body weight by up to 15.6% and atherogenic lipids including total cholesterol, LDL-C, and triglycerides by up to 15.1%, 11.2%, and 34.9%, respectively.”

   Human trialsubcutaneous48 weeksn = 254

   Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

More on Triglyceride

1. Pemvidutide decreases body weight in humans (up to 15.6%).

   “Pemvidutide reduced body weight by up to 15.6%”

   Human trialsubcutaneous48 weeksn = 391

   Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight

   ADA Scientific Sessions 2025 abstract·13 Jun 2025